(2-Hydroxy-2-methylpropyl)-trimethylazanium

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2-Hydroxy-2-methylpropyl)-trimethylazanium
• 化学式: C7H18NO+
• 分子量: 132.22
• InChiKey: XBJTWZKZOIUPOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• TREATMENT USING DANTROLENE
  申请人：Lyotropic Therapeutics, Inc.

  公开号：EP1603513A2

  公开（公告）日：2005-12-14
• AQUEOUS COMPOSITION COMPRISING DANTROLENE
  申请人：B. Braun Melsungen AG

  公开号：EP3364947A1

  公开（公告）日：2018-08-29
• [EN] TREATMENT USING DANTROLENE<br/>[FR] TRAITEMENT AU MOYEN DE DANTROLENE
  申请人：LYOTROPIC THERAPEUTICS INC

  公开号：WO2005013919A2

  公开（公告）日：2005-02-17

  Low volume safe for injection formulations of dantrolene yield significant advantages over the currently approved and marketed dantrolene for MH threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. Additionally, a safe for injection low volume formulation of dantrolene can be made widely available to non-anesthesiologist practitioners who have occasion to use dantrolene intravenously in the treatment of other potentially life threatening conditions, including in the field. The low volume, safe for injection formulations of dantrolene, as well as other formulations of dantrolene, have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.
• [EN] AQUEOUS COMPOSITION COMPRISING DANTROLENE<br/>[FR] COMPOSITION AQUEUSE COMPRENANT DU DANTROLÈNE
  申请人：BRAUN MELSUNGEN AG

  公开号：WO2017067980A1

  公开（公告）日：2017-04-27

  The present invention relates to an aqueous composition comprising either dantrolene or a pharmaceutically acceptable salt thereof and a cyclodextrin derivative wherein the pH of the aqueous composition is greater than 7. Further, the present invention relates to a powder obtained by drying the inventive composition as well as a kit comprising said inventive powder.